Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

Hung, Yi‐Jen; Chen, Y.-C.; Pei, Dee; Kuo, Shi‐Wen; Hsieh, Chang‐Hsun; Wu, Lee-Chen; He, Chih-Tsueng; Lee, C. H.; Fan, Sandra Chyi; Sheu, Wayne Huey Herng

doi:10.1111/j.1464-5491.2005.01569.x

Cited by 29 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Abbasi et al (46) showed that there were no alteration in serum adiponectin concentrations with significant improvement in insulin resistance after sibutramine treatment in insulin-resistant obese non-diabetic patients. Likewise, Hung et al (28) demonstrated that sibutramine treatment effectively reduced weight and enhanced insulin sensitivity without an alteration in serum adiponectin concentrations in obese type 2 diabetic patients. In other study, Tambascia et al (15) suggested that 6 months sibutramine treatment was effective in improving of HOMA-IR with no change in fibrinogen levels in the non-diabetic women.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, many studies showed that adiponectin levels changed with weight loss (26,27). However, in a recent study, treatment with sibutramine 15 mg once daily effectively reduced weight and enhanced insulin sensitivity without alteration of serum adiponectin levels in obese patients with type 2 diabetes (28).…”

Section: Introductionmentioning

confidence: 99%

“…Elevated circulating levels of cytokines and inflammatory markers, such as interleukin-6 (IL-6), C-reactive protein (hsCRP) and tumor necrosis factor-alpha (TNF-α) have been implicated to play role in the obesity (16,19,21,22). Previous studies demonstrated that sustained weight loss was associated with reduction of cytokines (23,24) and improved insulin sensitivity (15,28). Marfella et al (25) suggested that mean levels of TNF-α and hsCRP were decreased in obese women that lost at least 10% of their original weight, after 1 year of a multidisciplinary program of weight reduction.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

Sarac¹,

Saraç²

2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine ABS TRACTObjective: The aims of present study were 1) to evaluate cardiac valve characteristics, 2) to determine the plasma concentrations of fibrinogen, high sensitivity C-reactive protein (hsCRP), adiponectin, and tumor necrosis factor-α (TNF-α) in the obese women before and after 19 months sibutramine treatment in the obese women. Methods: Sixty obese women were enrolled in this prospective, randomized study. Thirty women received 10 mg once daily dose of sibutramine for 19 months. The rest of the obese women received 15 mg once daily dose of sibutramine for 19 months. All patients were evaluated with echocardiography. Plasma levels of adiponectin and TNF-α were measured by enzyme-linked immunosorbent assay (ELISA) and hsCRP by immunoturbimetric assay. Student paired and unpaired t tests were used to compare the 10 mg or 15 mg dose sibutramine effects either in groups or between the groups. Results: There were no signs of significant regurgitation or thickening of the mitral and aortic valves on echocardiographic evaluation performed after 19 months of treatment. Parameters of systolic function after 10 or 15 mg treatment were not different from pretreatment characteristics. Minimal tricuspid regurgitation was found in one (1/27) patient treated with 10 mg sibutramine after 19 months. Among obese patients treated with 15 mg sibutramine one patient (1/28) had minimal mitral valve regurgitation and 2 patients (2/28) had minimal aortic insufficiency. Stage II diastolic dysfunction in the 15 obese treated with 15 mg regressed to stage I diastolic dysfunction (50%). Stage II diastolic dysfunction in the 10 obese treated with 10 mg regressed to stage I diastolic dysfunction (33.3%). Mean levels of TNF-α(p=0.04), fibrinogen (p=0.03) and hsCRP (p=0.04)i decreased and adiponectin (p=0.03) levels increased in the obese treated with 10 mg sibutramine. Likewise, in the patients treated with 15 mg sibutramine, mean levels of TNF-α(p=0.01), fibrinogen (p= 0.02), and hsCRP (p= 0.04) decreased and adiponectin (p= 0.02) levels increased. Conclusion: Nineteen months of sibutramine treatment does not affect heart valve and systolic functions, however, diastolic dysfunction severity reduced with sibutramine treatment. Also In addition, mean levels of adiponectin, TNF-α, fibrinogen and hs-CRP change with 19 months sibutramine treatment. (Anadolu Kardiyol Derg 2010; 10: 226-32)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

Sarac¹,

Saraç²

2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

show abstract

“…[76][77][78][79] Sibutramine reduced high sensitivity C-reactive protein (hsCRP) levels in some studies 80,81 but not in others. 82 Sibutramine along with diet and exercise reduced the serum levels of the pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin 6 (IL-6) and increased the serum levels of the anti-inflammatory cytokine IL-10. 83 These anti-inflammatory effects were independent of weight loss in some studies 80 but were related to weight loss in others.…”

Section: Sibutramine and Cardiometabolic Risk Factorsmentioning

confidence: 99%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

“…In one study, adiponectin levels remained unchanged by treatment with sibutramine even though modest weight loss was achieved; however, another study observed increases in adiponectin levels. 62,63 Common side effects include an increase in blood pressure and pulse rate, 59 therefore it should be used with care in patients with high blood pressure.…”

Section: Therapies For Weight Lossmentioning

confidence: 99%

The importance of treating cardiometabolic risk factors in patients with type 2 diabetes

Barnett

2008

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

C ardiometabolic risk factors are the combined vascular and metabolic components of risk that may lead to a cardiovascular event. There are numerous such factors. Underlying the concept of cardiometabolic risk is an association with excess visceral fat, leading to the dysregulation of the adipokines, the signalling proteins derived from adipose tissue. Changes in the levels of the adipokines -tumour necrosis factor-α, cholesteryl ester transfer protein and adiponectin, for example -can lead to alterations in insulin sensitivity and high-density lipoprotein cholesterol metabolism. At present, specific cardiometabolic risk factors are commonly managed on an individual basis. We are now moving from the era of single risk factor intervention, however, to multiple risk factor intervention in people at high cardiovascular risk, with the additional possibility of using new drug classes to target the underlying cardiometabolic problems more effectively.

show abstract

Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

Abstract: We conclude that treatment with sibutramine 15 mg once daily effectively reduces weight and enhances insulin sensitivity without alteration of serum adiponectin levels in obese patients with Type 2 diabetes.

Cited by 29 publications

References 29 publications

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

The use of sibutramine in the management of obesity and related disorders: An update

The importance of treating cardiometabolic risk factors in patients with type 2 diabetes

Contact Info

Product

Resources

About